LH · Q3 2025 Earnings

Cautious

Labcorp

Reported October 28, 2025

30-second summary

Revenue grew 8.6% YoY to $3.56B and non-GAAP EPS hit $4.18. The FY2025 revenue midpoint was cut 40bps on FX ($13M) and acquisition close timing, but the EPS midpoint was raised $0.05 (floor +$0.10, ceiling flat) and the FCF midpoint was raised $25M. Management quantified the 2026 PAMA exposure at ~$100M top and bottom line with only ~$25M of identified mitigation. The setup into February's 2026 guide is now the gating event.

Headline numbers

EPS

Q3 FY2025

$4.18

Revenue

Q3 FY2025

$3.56B

+8.6% YoY

Gross margin

Q3 FY2025

28.8%

Free cash flow

Q3 FY2025

$0.28B

Operating margin

Q3 FY2025

11.1%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$3.56B	+8.6%	$3.53B	+0.8%
EPS	$4.18	—	$4.35	-3.9%
Gross margin	28.8%	—	29.6%	-80bps
Operating margin	11.1%	—	11.2%	-10bps
Free cash flow	$0.28B	—	$0.54B	-48.4%

Guidance

FY2025 EPS midpoint raised modestly but Enterprise Revenue and segment growth guides lowered due to currency headwinds and acquisition timing; FCF slightly raised.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY2025	$16.05 to $16.50	$16.15 to $16.50	Low end raised $0.10; range narrowed by $0.10 (less upside potential)	Lowered
Enterprise Revenue Growth	FY2025	7.5% to 8.6%	7.4% to 8.0%	Midpoint lowered from 8.05% to 7.7% (−35 bps); high end lowered 60 bps	Lowered
Free Cash Flow	FY2025	$1.13 billion to $1.28 billion	$1.17 billion to $1.29 billion	Low end raised $40 million; high end raised $10 million; midpoint raised $25 million (reaffirmed from prior quarter's incremental raise)	Raised
Diagnostics Laboratories Revenue Growth	FY2025	7.0% to 8.0%	7.2% to 7.8%	Low end raised 20 bps; high end lowered 20 bps; range narrowed by 40 bps total	Lowered
Biopharma Laboratory Services Revenue Growth	FY2025	6.1% to 7.5%	5.7% to 7.1%	Low end lowered 40 bps; high end lowered 40 bps; midpoint lowered 40 bps (−0.40 pts)	Lowered

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Diagnostics Laboratories	$2.77B	+8.5%
Biopharma Laboratory Services	$0.799B	+8.3%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Diagnostics Laboratories Adjusted Operating Margin	16.3%
Biopharma Laboratory Services Adjusted Operating Margin	16.5%
Consolidated Adjusted Operating Margin	14.4%
Diagnostics Organic Revenue Growth	6.3%
Biopharma TTM Net Orders	$3.34B
Biopharma Backlog	$8.58B
Biopharma Book to Bill Ratio	1.09
Diagnostics Total Requisition Growth	4.7%

Management tone

Steady operational momentum → organic volume re-acceleration → platform-economics confidence → navigating FX and PAMA headwinds.

The tonal pivot from Q2 to Q3 is sharp. Last quarter management was raising every FY line and explicitly reframing organic volume growth as a structural step-change. This quarter, despite Q3 organic volume holding at 3.5%, the FY revenue ceiling was cut by 60bps and the EPS ceiling went untouched. The phrase that does the most work in the release is the explicit attribution of the midpoint cut to "currency and acquisition timing" — language that didn't appear at all in Q2.

Last quarter PAMA was being actively negotiated in three parallel paths (legislation, delay, data submission), with management hinting that the ~$100M gross exposure shouldn't be fully embedded. This quarter Adam Schechter quantified planning assumptions concretely: $100M top and bottom line in 2026, $25M identified mitigation, Results Act with "bipartisan support" but timing uncertain due to government shutdown. That's not a tone of negotiation — that's a tone of preparing investors for a real hit and pushing the 2026 conversation to February.

The Q2 framing of specialty testing as a platform-anchor pull-through engine survived, but the consumer business disclosure went the other direction. Schechter acknowledged "very significant growth in its growth rate" while explicitly declining to quantify it — a posture more consistent with managing expectations than with announcing momentum.

The Q3 release also discloses a $50M annualized revenue divestiture in early development, framed as site consolidation and expected to improve operating income. That's portfolio pruning, not growth investment, and the symmetric narrowing of the Biopharma segment guide (−40bps midpoint) signals "tighter visibility" rather than "more confidence."

Q&A highlights

Lisa Gill · JP Morgan

Asked about revenue guidance reduction, specifically whether the 40 basis point cut was driven by currency or acquisitions, and whether there is any uptick in ACA-related utilization from patients anticipating benefit loss.

Julia Wang clarified that $13 million of the 40 bp cut came from FX and the remainder from acquisition timing (not margin-impacting, purely timing-related to deal closures). On utilization, management stated they are seeing 3.5% organic volume growth driven by demographics and market share gains, not ACA-related panic, because doctor appointment capacity is already saturated.

40 bp guidance reduction: $13M from FX, remainder from acquisition timingOrganic volume growth: 3.5%Diagnostic revenue growth: 8.5% (6% organic)No material ACA-driven utilization spike expected

Patrick Donnelly · Citi

Asked about PAMA implementation risk, the $100M top-line impact previously disclosed, mitigation efforts (~$25M), probability of legislative delay or Results Act passage, and management's planning assumptions for 2026.

Adam Schechter stated the company believes CMS's PAMA execution is inaccurate and advocates for the Results Act (which has bipartisan support). Acknowledged uncertainty due to government shutdown and competing legislative priorities. Current planning assumes $100M impact to both top line and bottom line in 2026, with ~$25M mitigation underway via AI efficiency gains and Launchpad offsets (which cover inflation). Final 2026 guidance will be provided in February.

$100M projected PAMA impact (top line and bottom line) for 2026~$25M mitigation plannedResults Act has bipartisan support but legislative timing uncertainLaunchpad covers inflation separately from PAMA mitigation

Jack Meehan · Nefron Research

Asked for detail on the $50M early development revenue divestiture/site consolidation decision, the market factors driving it, and the earnings impact.

Adam Schechter explained that early development is seeing delayed study starts despite stable RFPs, win rates, and market share. The $50M divestiture targets non-core areas via site consolidation and is expected to improve operating income despite lower revenue, implying the divested business was margin-dilutive. Central Labs remain strong (up 10%, or 7% constant currency).

$50M annualized revenue divestiture in early development non-core areasRFPs stable, win rates stable, market share stableStudy start timing delays are the core driverExpected slight improvement in operating income despite revenue loss

Aaron Wright · Morgan Stanley

Asked about consumer-driven testing contribution, growth rate, margin profile, and whether it is moving the needle on overall volume and revenue.

Adam Schechter stated that consumer business is experiencing very significant growth in its growth rate and continues to add new tests (lead exposure, ApoB, healthy aging), but has not yet reached critical mass to warrant separate reporting. Management engages ~75M patients across all channels and expects continued growth, will separate reporting when critical mass is achieved.

~75M patients engaged across all LabCorp channelsSignificant growth in consumer business growth rate (unquantified)New tests added: lead exposure, ApoB, healthy aging panelOvia Health app reaches women across pregnancy, postpartum, menopause stages

Kevin Caliendo · UBS

Asked whether margins in Q3 were as strong as expected, whether there was discretionary spend, and whether PAMA-related net impact of $70-75M would jeopardize long-range plan achievement in 2026.

Julia Wang attributed Q3 margin profile to normal puts/takes (Invitae benefits offset by new hospital deal integration dilution, Launchpad covering inflation). Adam Schechter said it is too early to provide 2026 specifics but management is working to offset PAMA via Launchpad and new AI initiatives; final 2026 guidance in February will clarify LRP compatibility.

110 bp margin expansion in Diagnostics driven by Invitae and LaunchpadHospital deals start dilutive and improve over time20 bp margin improvement in BLSPAMA impact ~$75M net (top line + bottom line)

Answers to last quarter's watch list

Organic volume growth holding at or above 3% — Held. Q3 organic volume growth at 3.5% per Julia Wang's Q&A response to Lisa Gill, consistent with prior framing. Diagnostics organic revenue growth was 6.3% with total requisition growth of 4.7%. The trajectory thesis is intact for one more quarter.

Resolved positively

Biopharma TTM book-to-bill above 1.10 — Slipped. Q3 TTM book-to-bill came in at 1.09, just under the threshold. Backlog of $8.58B was up 5.4% YoY per the press release. Not a collapse, but the leading indicator weakened by one tick.

Continue monitoring

PAMA legislative trajectory — Negative resolution. The government shutdown and competing legislative priorities have stalled momentum on the Results Act, and management is now planning for a full $100M 2026 hit with only $25M of identified mitigation. There's no concrete delay or data-submission framework on the table — the overhang is more concrete, not less.

Resolved negatively

Diagnostics Labs adjusted operating margin trajectory — Mixed. Q3 margin of 16.3% was +110bps YoY, driven by organic demand and Invitae, but management flagged new hospital deal integration dilution as an ongoing mix headwind. Q4 expected to moderate sequentially on typical seasonality.

Continue monitoring

Specialty testing growth disclosure as a separate line — Not disclosed. Management continues to discuss specialty as a platform-anchor concept without breaking out revenue. The consumer testing line got a similar "not yet at critical mass" treatment in Aaron Wright's question.

Continue monitoring

What to watch into next quarter

February 2026 guidance — gating event for the thesis. Watch whether the initial 2026 EPS bridge fully absorbs the $100M PAMA hit minus $25M mitigation, or whether additional offsets (AI initiatives, further Launchpad savings) close more of the gap. A 2026 EPS guide below ~$17.00 would imply the long-range plan is being reset.

Diagnostics adjusted operating margin durability. Hospital deal dilution is the stated mix headwind; either margin holds in Q4/Q1 as deals mature, or the dilution becomes structural. Watch the Q4 print against management's "moderate sequentially" framing.

Biopharma TTM book-to-bill — needs to recover above 1.10. Q3 print of 1.09 is the first slip below the threshold since the recovery narrative began. A second consecutive quarter below 1.10 would signal early development demand is softening again, not just experiencing study-start timing delays.

Q4 implied segment growth deceleration. Both segments printed Q3 growth above the new FY ceilings — implying meaningful Q4 deceleration is embedded in the guide. Either Q4 comes in conservative (validating guide) or it surprises to the upside (suggesting management sandbagged). Watch the gap.

Consumer business quantification. Management dodged sizing this quarter but flagged "very significant growth." A Q4 disclosure that includes a revenue contribution figure, even directionally, would signal confidence the segment is approaching critical mass.

Sources

Labcorp Q3 2025 Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/form8-kexhibit9913q25.htm
Labcorp Q3 2025 earnings call Q&A (transcript excerpts via internal extraction)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.